Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvimopan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 14/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 11/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvimopan SCHEMBL19367975 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL12188165 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL16449956 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL13913401 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL19367933 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL14995531 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL25348849 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL49578 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL1477341 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Alvimopan SCHEMBL8786261 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1OPRK1KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION | 2015-05-07 | — | — | US | claimed |
| US-8946262-B2 | Methods of preventing and treating gastrointestinal dysfunction | ADOLOR CORPORATION (US) | 2015-02-03 | — | — | US | claimed |
| US-20060211733-A1 | Methods of preventing and treating opioid bowel dysfunction | ADOLOR CORPORATION (US) | 2006-09-21 | — | — | US | claimed |
| WO-2006096577-A2 | METHODS OF PREVENTING AND TREATING OPIOID BOWEL DYSFUNCTION | ADOLOR CORPORATION (US) | 2006-09-14 | — | — | WO | claimed |
| US-20050148630-A1 | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | claimed |
| WO-2005055953-A2 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | claimed |
| WO-2005056011-A1 | METHODS OF PREVENTING AND TREATING NON-OPIOID INDUCED GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | claimed |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | MERCK SHARP & DOHME LLC | 2005-06-09 | — | — | US | claimed |
| US-20210145825-A1 | USE OF OPIOID ANTAGONISTS | THE UNIVERSITY OF CHICAGO | 2021-05-20 | — | — | US | disclosed |
| EP-2278966-B1 | TREATMENT WITH OPIOID ANTAGONISTS AND MTOR INHIBITORS | UNIV CHICAGO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10383869-B2 | Treatment with opioid antagonists and mTOR inhibitors | THE UNIVERSITY OF CHICAGO (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180098947-A1 | PARTICLES CONTAINING AN OPIOID RECEPTOR ANTAGONIST AND METHODS OF USE | THE UNIVERSITY OF CHICAGO | 2018-04-12 | — | — | US | disclosed |
| US-20180008594-A1 | USE OF OPIOID ANTAGONISTS | THE UNIVERSTIY OF CHICAGO | 2018-01-11 | — | — | US | disclosed |
| US-20170258909-A1 | USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION | THE UNIVERSITY OF CHICAGO | 2017-09-14 | — | — | US | disclosed |
| WO-2005056011-A1 | METHODS OF PREVENTING AND TREATING NON-OPIOID INDUCED GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | MERCK SHARP & DOHME LLC | 2005-06-09 | — | — | US | disclosed |
| EP-0657428-B1 | Preparation of 3,4,4-trisubstitutedpiperidinyl-n-alkylcarboxylates and intermediates, useful as opioid antagonists | LILLY CO ELI (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0984004-A2 | Trisubstituted-piperidinyl-N-alkylcarboxylates as opioid antagonists | ELI LILLY AND COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5434171-A | Gastrointestinal disorders; alvimopan | ELI LILLY AND COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0657428-A1 | Preparation of 3,4,4-trisubstitutedpiperidinyl-n-alkylcarboxylates and intermediates, useful as opioid antagonists | ELI LILLY AND COMPANY (US) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383869-B2 | Treatment with opioid antagonists and mTOR inhibitors | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20060211733-A1 | Methods of preventing and treating opioid bowel dysfunction | OPRK1, SLC10A2, SI | OPRM1 5/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20180098947-A1 | PARTICLES CONTAINING AN OPIOID RECEPTOR ANTAGONIST AND METHODS OF USE | OPRM1, OPRK1, OGFR | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | VIP, FABP2, SI | OPRM1 401/4885OPRD1 128/4885OPRK1 135/4885 |
| US-20210145825-A1 | USE OF OPIOID ANTAGONISTS | OGFR, OPRL1, OPRK1 | OPRM1 4/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | PNMT, VIP, PREP | OPRM1 70/4885OPRD1 5/4885OPRK1 9/4885 |
| US-20050148630-A1 | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction | SLC10A2, OPRK1, FABP2 | OPRM1 7/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20170258909-A1 | USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION | OGFR, OPRK1, OPRL1 | OPRM1 4/4885OPRD1 5/4885OPRK1 2/4885 |
| US-20180008594-A1 | USE OF OPIOID ANTAGONISTS | OGFR, OPRL1, OPRK1 | OPRM1 4/4885OPRD1 5/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.